Can I read EM2D9, A monoclonal antibody against integrin α5β1, has potent antitumor activity on endometrial cancer in vitro and in vivo on EtoBox?

EM2D9, A monoclonal antibody against integrin α5β1, has potent antitumor activity on endometrial cancer in vitro and in vivo by Yinyan Xu; Yi Li; Jiahui Pan; Xing Kang; Xu Zhang; Xinyi Feng; Shucheng Li; Chengxi Li; Jinku Zhang; Chong Li; Guoqing Wang is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is EM2D9, A monoclonal antibody against integrin α5β1, has potent antitumor activity on endometrial cancer in vitro and in vivo about?

Endometrial cancer, a type of primary epithelial malignant tumor in the endometrium, is one of the three most common malignant tumors of the female reproductive system. While the incidence of endometrial cancer has been recently rising, its etiology remains unclear. In this study we found that EM2D9, an independently developed monoclonal antibody, specifically recognized endometrial cancer cells; we further determined that EM2D9 target protein was α5β1. In vitro and in vivo experiments showed that EM2D9 inhibited the migration of endometrial cancer cells. Real-time quantitative PCR results showed that the expression of CD151 mRNA in endometrial carcinoma cells significantly decreased after EM2D9 treatment. We also found that EM2D9 affected the FAK signaling pathway. Collectively, these results shed light on a new mechanism for the development of endometrial carcinoma.

Who reads EM2D9, A monoclonal antibody against integrin α5β1, has potent antitumor activity on endometrial cancer in vitro and in vivo?

Author

Yinyan Xu; Yi Li; Jiahui Pan; Xing Kang; Xu Zhang; Xinyi Feng; Shucheng Li; Chengxi Li; Jinku Zhang; Chong Li; Guoqing Wang

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0304-3835)

Published

2020

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)